## **Resource Summary Report**

Generated by NIF on May 11, 2025

# **Biomarkers Across Neurodegenerative Diseases**

RRID:SCR 004015

Type: Tool

## **Proper Citation**

Biomarkers Across Neurodegenerative Diseases (RRID:SCR\_004015)

#### **Resource Information**

URL: http://www.alz.org/research/alzheimers\_grants/biomarkers-across.asp

**Proper Citation:** Biomarkers Across Neurodegenerative Diseases (RRID:SCR\_004015)

**Description:** Consortium that launched a Request for Applications (RFA) to stimulate analyses across the Alzheimer's disease (AD) and Parkinson's disease (PD) research enterprises to engage in further data analysis of existing cohorts, including, but not limited to, biomarker discovery, standardization of assays, genetic profiles, and imaging modalities. The RFA aims to build on existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also potentially biologically. The RFA is designed to enable preliminary pilot research or proof-of-principle studies utilizing data and/or samples from two large biomarker studies, the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Parkinson's Progression Markers Initiative (PPMI), in order to garner further research support from other funding agencies. Application Deadline: March 19, 2014. Efforts under BAND include studies that: \* analyze datasets to test hypotheses related to aging and neurodegenerative disorders; \* seek to identify panels or pathways that may play a role in disease mechanisms, such as around inflammation; \* pursue shared or disparate biochemical markers of disease risk, onset or progression; \* assess potential commonalities across the disease spectrum, including around other neurological disorders such as Lewy body dementia. Recent data reported at the 2013 Alzheimer's Association's International Conference stimulated discussion in the research community about the possible cross talk between AD and PD. For example, underlying pathologies / biomarkers, such as cerebrospinal fluid (CSF) alpha-synuclein, have been measured in the sample sets collected for both diseases to help understand similarities and differences in these diseases. Furthermore, similar imaging modalities, such as MRI and PET, are being employed to interrogate changes that occur with disease progression. As therapeutic approaches are developed that may be disease-modifying for several neurodegenerative diseases,

stratification of clinical trial populations based on biomarker profiles may increase the probability of success in demonstrating a beneficial effect.

**Abbreviations: BAND** 

Resource Type: portal, data or information resource, consortium, funding resource,

organization portal

**Keywords:** biomarker, grant, standardization, assay, genetic profile, neuroimaging, request

for application, data acquisition, method, quality control

Funding: alz.org;

Michael J. Fox Foundation for Parkinson's Research;

Weston Brain Institute

Resource Name: Biomarkers Across Neurodegenerative Diseases

Resource ID: SCR\_004015

Alternate IDs: nlx\_158434

**Record Creation Time:** 20220129T080222+0000

**Record Last Update:** 20250509T055634+0000

### **Ratings and Alerts**

No rating or validation information has been found for Biomarkers Across Neurodegenerative Diseases.

No alerts have been found for Biomarkers Across Neurodegenerative Diseases.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We have not found any literature mentions for this resource.